Search
IN01
go.drugbank.com/drugs/DB16434ExperimentalThe IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria[L30543]. … Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130).
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalA phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalSimilar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949).
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
go.drugbank.com/drugs/DB16443InvestigationalThese promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants. … The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853].
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene.
Synonyms: DeltaRex-G Retroviral Vector Encoding a Cyclin G1 InhibitorVeru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. These trials aimed to evaluate its effi...
Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]
Tozorakimab
go.drugbank.com/drugs/DB16473Investigationalhistory of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a